(0.69%) 5 163.38 points
(0.27%) 38 779 points
(0.77%) 16 281 points
(0.20%) $78.27
(4.67%) $2.24
(1.04%) $2 332.70
(3.53%) $27.63
(-0.07%) $964.60
(-0.09%) $0.928
(-0.42%) $10.83
(-0.17%) $0.796
(-0.13%) $91.33
0.00% $ 38.39
Live Chart Being Loaded With Signals
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally...
Stats | |
---|---|
Tagesvolumen | 200.00 |
Durchschnittsvolumen | 13.00 |
Marktkapitalisierung | 0.00 |
Last Dividend | $0.411 ( 2022-05-12 ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Vifor Pharma AG Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Vifor Pharma AG Finanzdaten
Annual | 2021 |
Umsatz: | $1.82B |
Bruttogewinn: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2021 |
Umsatz: | $1.82B |
Bruttogewinn: | $1.15B (63.18 %) |
EPS: | $0.445 |
FY | 2020 |
Umsatz: | $1.71B |
Bruttogewinn: | $1.00B (58.89 %) |
EPS: | $1.108 |
FY | 2019 |
Umsatz: | $1.88B |
Bruttogewinn: | $1.12B (59.44 %) |
EPS: | $0.490 |
Financial Reports:
No articles found.
Vifor Pharma AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.371 | 2016-05-02 |
Last Dividend | $0.411 | 2022-05-12 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | $2.44 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.49 | |
Div. Directional Score | 6.33 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VWAGY | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
KIGRY | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
BSPA | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
SCGLY | Ex Dividend Junior | 2023-05-25 | Annually | 0 | 0.00% | |
FIDS | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
MHGU | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
CLCGY | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
STWRY | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
HCMLY | Ex Dividend Knight | 2023-05-09 | Annually | 0 | 0.00% | |
AILLM | Ex Dividend Knight | 2023-07-14 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.145 | 1.500 | 7.09 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0520 | 1.200 | 8.27 | 9.92 | [0 - 0.3] |
returnOnEquityTTM | 0.0752 | 1.500 | -0.276 | -0.414 | [0.1 - 1] |
payoutRatioTTM | 0.715 | -1.000 | 2.85 | -2.85 | [0 - 1] |
currentRatioTTM | 1.914 | 0.800 | 5.43 | 4.34 | [1 - 3] |
quickRatioTTM | 1.013 | 0.800 | 8.75 | 7.00 | [0.8 - 2.5] |
cashRatioTTM | 1.013 | 1.500 | 5.49 | 8.23 | [0.2 - 2] |
debtRatioTTM | 0.115 | -1.500 | 8.08 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 22.19 | 1.000 | 2.89 | 2.89 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.53 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.168 | -1.500 | 9.33 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.632 | 1.000 | 2.80 | 2.80 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.109 | 1.000 | 9.81 | 9.81 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.898 | 1.000 | 6.12 | 6.12 | [0.2 - 2] |
assetTurnoverTTM | 0.358 | 0.800 | -0.948 | -0.758 | [0.5 - 2] |
Total Score | 10.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 42.61 | 1.000 | 5.80 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0752 | 2.50 | -0.177 | -0.414 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.949 | 2.00 | 9.68 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.622 | 2.00 | 9.46 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.715 | 1.500 | 2.85 | -2.85 | [0 - 1] |
pegRatioTTM | -2.43 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.289 | 1.000 | 5.27 | 0 | [0.1 - 0.5] |
Total Score | 2.49 |
Vifor Pharma AG
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.